EA201992135A1 - Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета - Google Patents

Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета

Info

Publication number
EA201992135A1
EA201992135A1 EA201992135A EA201992135A EA201992135A1 EA 201992135 A1 EA201992135 A1 EA 201992135A1 EA 201992135 A EA201992135 A EA 201992135A EA 201992135 A EA201992135 A EA 201992135A EA 201992135 A1 EA201992135 A1 EA 201992135A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
pancreatic
source
stem cells
surrogate
Prior art date
Application number
EA201992135A
Other languages
English (en)
Inventor
Уилльям Л. Раст
Original Assignee
Серексис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Серексис, Инк. filed Critical Серексис, Инк.
Publication of EA201992135A1 publication Critical patent/EA201992135A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1329—Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Свежую ткань поджелудочной железы человека можно использовать в качестве источника клеток для идентификации и отбора популяции нестволовых клеток, которая может стать источником суррогатных клеток поджелудочной железы, которые можно использовать для лечения инсулинозависимого сахарного диабета. Клетки-предшественники указанных суррогатных клеток поджелудочной железы не имеют репрограммирующих генов, интегрированных в их геном, дифференцируются в панкреатическом направлении в соответствии с протоколом, в котором используют только определенные реагенты, и, по существу, не способны к дифференцировке в мезодермальном направлении.
EA201992135A 2012-06-26 2013-06-24 Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета EA201992135A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261664259P 2012-06-26 2012-06-26

Publications (1)

Publication Number Publication Date
EA201992135A1 true EA201992135A1 (ru) 2020-02-05

Family

ID=48746139

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590088A EA033954B1 (ru) 2012-06-26 2013-06-24 Неплюрипотентные клетки-предшественники суррогатных клеток поджелудочной железы и способ их получения
EA201992135A EA201992135A1 (ru) 2012-06-26 2013-06-24 Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201590088A EA033954B1 (ru) 2012-06-26 2013-06-24 Неплюрипотентные клетки-предшественники суррогатных клеток поджелудочной железы и способ их получения

Country Status (16)

Country Link
US (2) US9968639B2 (ru)
EP (2) EP2864473B1 (ru)
JP (2) JP6386453B2 (ru)
KR (2) KR102058259B1 (ru)
CN (2) CN104640979B (ru)
AU (2) AU2013280698B2 (ru)
BR (1) BR112014031676A2 (ru)
CA (1) CA2876677C (ru)
DK (1) DK2864473T3 (ru)
EA (2) EA033954B1 (ru)
ES (1) ES2745704T3 (ru)
IL (2) IL236346B (ru)
IN (1) IN2015DN00281A (ru)
PT (1) PT2864473T (ru)
SG (1) SG11201408717XA (ru)
WO (1) WO2014004341A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106467918B (zh) * 2015-08-18 2020-07-31 中国科学技术大学先进技术研究院 一种基于人皮肤细胞的胰岛素分泌细胞的诱导方法及应用
CN105434471A (zh) * 2015-11-26 2016-03-30 深圳爱生再生医学科技有限公司 治疗糖尿病的干细胞制剂及其制备方法
AU2019218122A1 (en) * 2018-02-09 2020-09-24 Seraxis, Inc. Pancreatic cells for treating diabetes and methods of generating the same
CN112888778A (zh) * 2018-10-15 2021-06-01 Cynity株式会社 通过低分子化合物由源自内胚层组织或器官的细胞制备干细胞/祖细胞的方法
AU2020403679A1 (en) * 2019-12-11 2022-07-07 The University Of Tokyo Induction of proliferous pancreatic islet precursor cell-like cells by transient expression of Mycl and induction of differentiation into insulin-positive cells
WO2023278382A1 (en) 2021-06-29 2023-01-05 Staffan Holmin Endoluminal delivery cannula
US20230330264A1 (en) 2022-04-15 2023-10-19 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861313A (en) * 1995-06-07 1999-01-19 Ontogeny, Inc. Method of isolating bile duct progenitor cells
WO2000040722A2 (en) 1999-01-07 2000-07-13 Incyte Pharmaceuticals, Inc. Insulin-synthesis genes
US6815203B1 (en) 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US6866843B2 (en) 1999-12-06 2005-03-15 Viacell, Inc. Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6436704B1 (en) * 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
JP2005537803A (ja) 2002-09-06 2005-12-15 アムサイト インコーポレーティッド Ｃｄ５６陽性ヒト成体膵臓内分泌前駆細胞
EP1636348B1 (en) 2003-06-20 2009-07-29 Vrije Universiteit Brussel VUB Method of generating islet beta-cells from exocrine pancreatic cells
AU2005221095A1 (en) * 2004-03-09 2005-09-22 John J. O'neil Methods for generating insulin-producing cells
US20060029987A1 (en) 2004-08-06 2006-02-09 Applera Corporation Diagnosis of pancreatic cancer by using pancreatic targets
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
AU2007277341A1 (en) * 2006-07-19 2008-01-31 University Of Florida Research Foundation, Inc. Compositions for reprogramming a cell and uses therefor
US20100204258A1 (en) 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
CN101765657A (zh) 2007-11-09 2010-06-30 Rnl生物技术株式会社 分离和培养来自人羊膜上皮细胞的成人干细胞的方法
JP5429755B2 (ja) * 2008-04-18 2014-02-26 国立大学法人名古屋大学 間葉系幹細胞およびその生産方法
WO2009136168A1 (en) 2008-05-09 2009-11-12 The University Court Of The University Of Glasgow Materials and methods relating to cell based therapies
US9683215B2 (en) * 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
EP2379577A4 (en) * 2008-12-23 2012-08-29 Vivoscript Inc COMPOSITIONS AND METHODS FOR CELL REPROGRAMMING WITHOUT GENETIC MODIFICATION
US20120263689A1 (en) * 2009-09-10 2012-10-18 The Salk Institute For Biological Studies Adipose-derived induced pluripotent stem cells
EP2569419B1 (en) * 2010-05-12 2019-03-20 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012025914A1 (en) * 2010-08-22 2012-03-01 Ramot At Tel-Aviv University Ltd. Induced pluripotent stem cells derived from human pancreatic beta cells
US9181528B2 (en) * 2010-08-31 2015-11-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
EP2616539A1 (en) * 2010-09-15 2013-07-24 Ramot at Tel-Aviv University Ltd. Methods of expanding and redifferentiating islet beta cells
WO2012044486A1 (en) * 2010-09-28 2012-04-05 Baylor Research Institute Induction of pancreatic stem cells by transient overexpression of reprogramming factors and pdxi selection

Also Published As

Publication number Publication date
US9968639B2 (en) 2018-05-15
AU2013280698A1 (en) 2015-01-22
JP6856586B2 (ja) 2021-04-07
US20150231181A1 (en) 2015-08-20
EA033954B1 (ru) 2019-12-13
WO2014004341A1 (en) 2014-01-03
IL236346B (en) 2019-06-30
AU2019202085A1 (en) 2019-04-18
IN2015DN00281A (ru) 2015-06-12
KR102174581B1 (ko) 2020-11-06
CN113265370A (zh) 2021-08-17
EP3611255A1 (en) 2020-02-19
KR20190141263A (ko) 2019-12-23
CN104640979B (zh) 2021-05-04
US20130344594A1 (en) 2013-12-26
CN104640979A (zh) 2015-05-20
IL236346A0 (en) 2015-02-26
ES2745704T3 (es) 2020-03-03
DK2864473T3 (da) 2019-09-23
EA201590088A1 (ru) 2015-04-30
SG11201408717XA (en) 2015-02-27
AU2013280698B2 (en) 2019-01-17
JP6386453B2 (ja) 2018-09-05
KR20150036059A (ko) 2015-04-07
EP2864473B1 (en) 2019-08-21
CA2876677A1 (en) 2014-01-03
JP2015522281A (ja) 2015-08-06
PT2864473T (pt) 2019-09-27
US9474772B2 (en) 2016-10-25
CA2876677C (en) 2021-09-07
KR102058259B1 (ko) 2019-12-23
JP2018193394A (ja) 2018-12-06
IL266965A (en) 2019-07-31
IL266965B (en) 2021-08-31
BR112014031676A2 (pt) 2017-10-31
EP2864473A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
EA201992135A1 (ru) Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
MX2015016798A (es) Regulacion transcripcional guiada por acido ribonucleico.
EA201500314A1 (ru) Лекарственные формы энзалутамида
WO2014011901A3 (en) Methods and compositions for delivery of biologics
EA201590488A1 (ru) Способы модификации клеток-хозяев
EA201400993A1 (ru) Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
TN2014000438A1 (en) Anti-fcrn antibodies
EA201391773A1 (ru) Клетки-предшественники мезодермальной линии
PT2838548T (pt) Células deficientes em hla de classe ii, células deficientes em hla de classe i capazes de expressar proteínas de hla de classe ii, e utilizações das mesmas
GB201020995D0 (en) Biological materials and uses thereof
WO2011130624A3 (en) Sustained polypeptide expression from synthetic, modified rnas and uses thereof
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
MX365612B (es) Polipeptidos de factor x modificados y usos de los mismos.
WO2014153069A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
TW201611843A (en) Methods of treatment with arginine deiminase
MX2013004061A (es) Analogos de ciclosporina.
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
EA201590747A1 (ru) Способы лечения с использованием аденовируса
EA201690503A1 (ru) Антитела
TN2014000327A1 (en) Oligonucleotides for modulating gene expression and uses thereof
MX2013004062A (es) Analogos de ciclosporina.
MX2015008436A (es) Composiciones para permeabilizar celulas sanguineos fijos y sus usos.
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)